(Reuters) – Sanofi on Friday mapped out a potential separate listing of its consumer healthcare business from the fourth quarter of next year, as it plans to shore up new drug development spending at its core business.
The French group’s consumer business, which was put on course to be run on its own in late 2019, had 2022 sales of 5.1 billion euros ($5.4 billion), up 8.6%, with brand brands including Mucosolvan cough syrup, Allegra allergy treatments Buscopan against abdominal pain.
The following are similar recent transactions, or situations, at peers.
($1 = 0.9473 euros)
(Reporting by Ludwig Burger; editing by David Evans)
